Emily is an Associate Director of Clinical Sciences at Sangamo Therapeutics. Prior to joining Sangamo in October 2018, she was a Clinical Development Scientist on the Wiskott-Aldrich Syndrome (WAS) gene therapy programme at GlaxoSmithKline (GSK). Emily originally joined GSK in January 2016 as External Strategy Manager, Gene Therapy, looking at developing external partnerships and providing scientific input to the internal gene therapy strategy and pipeline, before moving to work as a clinical scientist on the WAS programme in January 2017. Emily has a background in Chemistry and Biochemical Engineering, working on engineering growth substrates for pluripotent stem cell bioprocessing during her PhD at University College London, UK (2006-2010). She is an active member of the cell and gene therapy community, including sitting on the International Society for Cell Therapy’s Executive Management Committee as Global Treasurer and acting as Chair for the American Society for Gene and Cell Therapy’s International Committee.